{
    "clinical_study": {
        "@rank": "126030", 
        "arm_group": [
            {
                "arm_group_label": "V501", 
                "arm_group_type": "Experimental", 
                "description": "V501: 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match V501: 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the efficacy, immunogenicity, and tolerability of V501 (quadrivalent\n      Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine,\n      GARDASIL\u2122) in healthy, 16- to 26-year old Japanese males. The hypotheses tested are: 1) V501\n      reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection\n      compared with placebo, and 2) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or\n      18-related persistent infection, condyloma acuminata, penile/perianal/perineal\n      intraepithelial neoplasia, or penile, perianal, or perineal cancer compared with placebo."
        }, 
        "brief_title": "Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anogenital Human Papilloma Virus Infection", 
            "Condyloma Acuminata"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Condylomata Acuminata", 
                "Papilloma", 
                "Virus Diseases", 
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Japanese\n\n          -  No clinical evidence of gross genital lesion suggesting sexually-transmitted disease\n             and no clinically present external genital warts\n\n          -  Other inclusion criteria will be discussed with the investigator during screening\n\n        Exclusion Criteria:\n\n          -  History of known prior vaccination with an HPV vaccine or plans to receive one\n             outside the study\n\n          -  History of external genital warts\n\n          -  History of severe allergic reaction that required medical intervention\n\n          -  Received immune globulin or blood-derived products in the past 6 months or plan to\n             receive any before Month 7 of the study\n\n          -  History of splenectomy, is currently immunocompromised, or has been diagnosed with\n             immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic\n             lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis,\n             inflammatory bowel disease, or other autoimmune condition\n\n          -  Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or\n             topical corticosteroids and certain regimens of systemic corticosteroids\n\n          -  Known thrombocytopenia or coagulation disorder that would contraindicate\n             intramuscular injections\n\n          -  Ongoing alcohol or drug abuse within the past 12 months"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "26 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "1100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862874", 
            "org_study_id": "V501-122", 
            "secondary_id": "132237"
        }, 
        "intervention": [
            {
                "arm_group_label": "V501", 
                "intervention_name": "V501", 
                "intervention_type": "Biological", 
                "other_name": [
                    "GARDASIL\u2122", 
                    "Quadrivalent HPV (Type 6, 11, 16 and 18) L1 Virus-Like Particle vaccine"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Japan Call Center", 
                "phone": "81-3-6272-1957"
            }, 
            "facility": {
                "address": {
                    "city": "Chiyoda-Ku, Tokyo", 
                    "country": "Japan", 
                    "zip": "102-8667"
                }, 
                "name": "MSD K.K."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Combined Incidence of HPV 6-, 11-, 16-, or 18-Related Persistent Infection", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Percentage of Participants with an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after any vaccination"
            }, 
            {
                "measure": "Percentage of Participants with Vaccine-Related Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862874"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Combined Incidence of HPV 6-, 11-, 16-, or 18-Related Persistent Infection, Condyloma Acuminata, Penile/Perianal/Perineal Intraepithelial Neoplasia, or Penile, Perianal, or Perineal Cancer", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 months"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}